SHS Capital

SHS Capital is a well-established independent private equity firm based in Tübingen, Germany, with a specialized focus on the MedTech and Life Sciences sectors. Founded in 1993, the firm has built a significant track record over three decades, primarily investing in growth equity opportunities within the German-speaking regions of Germany, Switzerland, and Austria. SHS Capital targets companies with revenues typically ranging from EUR 5 million to EUR 150 million, seeking to provide capital for expansion financing, shareholder changes, and succession solutions.

The firm's investment strategy is centered on identifying innovative and high-growth companies within its niche, leveraging its deep industry expertise to support their development. SHS Capital is known for its long-term investment horizon and active partnership approach with portfolio companies, aiming to foster sustainable growth and market leadership. A key indicator of their capacity is their recently closed SHS VI fund, which secured EUR 200 million in commitments in 2022, following the successful SHS V fund that raised EUR 130 million in 2018. These substantial funds underscore their continued commitment and ability to deploy significant capital into promising ventures.

SHS Capital typically provides substantial first cheques, with individual investments ranging from EUR 10 million to EUR 50 million per company. This significant check size positions them as a key player for mid-to-late-stage growth financing in the European MedTech and Life Sciences landscape. Their consistent focus on a specialized sector, combined with a robust capital base and a history spanning over 30 years, allows them to offer not just financial backing but also strategic guidance and access to a broad network within the healthcare industry. The firm's disciplined approach and sector-specific expertise make them a notable partner for companies seeking to scale and innovate in these critical fields.